Thomas Mundorf is an Ophthalmology physician affiliated with Charlotte Eye Ear Nose & Throat Associates. OpenAlex indexes 33 publications with 1,672 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
135 S Sharon Amity Rd Ste 100
Charlotte, NC 282113870
Telephone
704-365-0555Provider last certified this registry record 24 Feb 2026.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20251 payment
- Tarsus Pharmaceuticals, Inc.Program year20243 payments
- Amgen Inc.Program year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
90.9%Prostaglandin Analog35%Latanoprost62%Lumigan34%Travoprost4%Part D<11 patientsalpha-Adrenergic Agonist24.5%Brimonidine Tartrate39%Combigan35%Brimonidine Tartrate-Timolol17%Alphagan P9%Part D<11 patients+ 6 more classes in this area
Cardiovascular
5.7%Beta blocker5.7%Timolol Maleate100%Part D≥43 patientsCancer & immunology
3.4%Calcineurin inhibitor3.4%Restasis100%Part D≥33 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study
American Journal of Ophthalmology
2019 - A Phase 2 Randomized, Double-Masked, Placebo-Controlled Study of a Novel Integrin Antagonist (SAR 1118) for the Treatment of Dry Eye
American Journal of Ophthalmology
2012 - A Phase 2 Multicenter, Double-masked, Placebo-controlled Study Of A Novel Lymphocyte Function-associated Antigen-1 (LFA-1) Antagonist (SAR 1118) For Treatment Of Dry Eye2011
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”